Outlook Therapeutics (OTLK) Short term Debt: 2015-2019
Historic Short term Debt for Outlook Therapeutics (OTLK) over the last 4 years, with Sep 2019 value amounting to $6.7 million.
- Outlook Therapeutics' Short term Debt rose 9976.71% to $6.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $6.7 million, marking a year-over-year increase of 9976.71%. This contributed to the annual value of $6.7 million for FY2019, which is 9976.71% up from last year.
- According to the latest figures from Q3 2019, Outlook Therapeutics' Short term Debt is $6.7 million, which was down 0.00% from $6.7 million recorded in Q2 2019.
- Outlook Therapeutics' 5-year Short term Debt high stood at $12.8 million for Q2 2018, and its period low was $52,600 during Q3 2017.
- For the 3-year period, Outlook Therapeutics' Short term Debt averaged around $7.8 million, with its median value being $7.6 million (2019).
- Per our database at Business Quant, Outlook Therapeutics' Short term Debt slumped by 91.03% in 2017 and then spiked by 9,976.71% in 2019.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Short term Debt stood at $742,646 in 2015, then declined by 21.03% to $4.9 million in 2016, then soared by 147.11% to $12.2 million in 2017, then decreased by 25.70% to $9.1 million in 2018, then soared by 9,976.71% to $6.7 million in 2019.
- Its Short term Debt was $6.7 million in Q3 2019, compared to $6.7 million in Q2 2019 and $7.6 million in Q1 2019.